ArticleHealth science reports2026
Hepatic Enzyme Abnormalities and Their Association With Hematological Parameters in Sickle Cell Disease: A Case-Control Study in Cameroon.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The polymerization of deoxygenated hemoglobin S, resulting from a genetic mutation in sickle cell disease (SCD), leads to damage in multiple organs, including renal, cardiopulmonary, and cerebrovascular systems. The liver is also commonly affected, resulting in "sickle cell liver disease," which may lead to progressive fibrosis and impaired liver function in adulthood. We hypothesized that hepatic enzyme abnormalities are frequent in patients with sickle cell disease and are associated with underlying hematological alterations related to hemolysis. This study aimed to determine the frequency of hepatic enzyme abnormalities in patients with sickle cell disease and to examine their association with hematological parameters. Methods: A 4-month case-control study was conducted at the Hematology Department of the Bafoussam Regional Hospital. Following informed consent, blood samples were collected in EDTA tubes for complete blood counts (performed by flow cytometry) and in plain tubes for biochemical analyses. These included the enzymatic activities of alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT), measured using kinetic spectrophotometric methods, as well as albumin concentration, determined using a colorimetric spectrophotometric method. Based on these biochemical parameters, patterns of hepatocellular injury, cholestasis, and mixed liver injury were identified. Data were analyzed using R software version 4.1.1. Results: A total of 167 participants were enrolled, including 94 patients with homozygous sickle cell disease (SS) and 73 healthy controls (AA). ALT levels were significantly higher in patients than in controls, with median values of 18.2 U/L [14.0-26.7] versus 15.1 U/L [12.0-24.0] ( Conclusion: These findings indicate significant liver involvement in patients with sickle cell disease, characterized by hepatocellular injury, cholestasis, and impaired synthetic function. Regular biochemical monitoring of liver function is therefore essential to improve disease management and prevent complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.